New guidance from NICE recommends earlier use of SGLT-2 inhibitors and personalised treatment for people with type 2 diabetes ...

In a recent study published in the journal Signal Transduction and Targeted Therapy, researchers from Australia investigated the potential of small molecule inhibitors, specifically GSK126 (short for ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Treatment approaches have shifted with the introduction of targeted agents, notably Bruton tyrosine kinase (BTK) inhibitors, as well as the emerging role of immunotherapy, according to a new review ...

NICE recommends SGLT-2 inhibitors with metformin at diagnosis, citing major cardiovascular, renal, and mortality benefits.

BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced ...

Use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors rather than metformin as first-line treatment for type 2 diabetes appears to cut the risk for heart failure hospitalization but not myocardial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Sodium-glucose transport protein 2 (SGLT2) inhibitor ...

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), ...